In mid-August, the U.S. Department of Health and Human Services (HHS) announced that FDA would no longer require premarket review of laboratory developed tests (LDTs) (tests designed, manufactured, and used within a single laboratory), absent future legislation or notice and comment rulemaking. On October 7th, FDA announced that it would no longer review emergency use authorization requests for LDTs. There are competing views about whether FDA had previously overstepped its authority over LDTs and whether these changes could cause unreliable tests, including COVID-19 tests, to enter the market. This webinar will examine the history of FDA’s LDT regulation, HHS’s legal authority for revoking FDA’s premarket review process, whether the HHS announcement followed proper administrative law procedures, the effect of the HHS and FDA announcements on FDA’s regulation of both COVID and non-COVID LDT tests and FDA’s future use of enforcement discretion generally, and the progress of pending diagnostic reform legislation.


Alberto Gutierrez, Partner, NDA Partners LLC
Peter Lurie, Executive Director, Center for Science in the Public Interest
Tom Sparkman, Senior Vice President, Government Affairs and Policy, American Clinical Laboratory Association
Moderated by Jeffrey N. Gibbs, Director, Hyman, Phelps & McNamara, PC 



  • +$100 for non-members

Webinar & Recording

  • +$100 for non-members
Register Now


Internet Explorer and Microsoft Edge are not supported by the checkout process.

Please use Chrome, Firefox, or Safari.  If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.

An access link will be provided to attendees via email upon registration.

If you are registering on behalf of someone else, the link to access the webinar will go to the email address provided at the point of registration.

Those registering on the day of the webinar will receive an access link via email upon successful payment.

Please click the Test Your System link to determine your computer’s compatibility prior to the webinar.

Your organization may have strict IT policies that impede your ability to participate in the webinar. If you believe that may be the case, please perform the diagnostic test prior to purchasing a registration.

Yes! You may participate in the webinar from any contemporary smart phone or tablet. This requires a stable WIFI or data connection.

Please click the Test Your System link to determine your device’s compatibility prior to the webinar.

No, webinar content including audio is streamed through your computer or mobile device.

Please click the Test Your System link to determine your device’s compatibility prior to the webinar.

Webinar recordings are sent via email as soon as we are able to process and verify the quality of the recording. This usually occurs within 3 business days of a webinar broadcast.

If multiple people at your organization wish to participate from separate devices, each will be required to purchase access.